A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma

E. M. Hersh(Arizona Oncology), Axel Hauschild(University Hospital Schleswig-Holstein), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Michael P. Brown(South Australia Pathology), Alessandro Testori(European Organisation for Research and Treatment of Cancer), M. Li, Scott Ernst(Western University), Shailender Bhatia(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Alicia Clawson(Epizyme (United States)), Kari Kendra(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Carrie Baker Brachmann(Gilead Sciences (United States)), Jean‐Jacques Grob(Aix-Marseille Université), Sanjiv S. Agarwala(Goethe University Frankfurt), Richard Kefford(Broad Institute), Markus F. Renschler(Princess Margaret Cancer Centre), Robert M. Conry(University of Alabama), Jade Homsi(The University of Texas MD Anderson Cancer Center), Carmen Loquai(Johannes Gutenberg University Mainz), Andrew Haydon(The Alfred Hospital), Caroline Robert(Institut Gustave Roussy), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), I. Elias, Maha Karnoub

Annals of Oncology

September 27, 2015

Cited by 97

|New England Journal of Medicine|2012|8k

|New England Journal of Medicine|2011|7.7k

|New England Journal of Medicine|2013|6.6k

|New England Journal of Medicine|2015|5.9k

|New England Journal of Medicine|2014|5.3k

Related Papers